MediPharm Labs Corp. MEDIF LABS said Thursday it has entered into a manufacturing agreement for the filling and packaging of vaporizer devices for Cronos Cronos Group Inc's CRON CRON adult-use brand, COVE.
Per the agreement, the company’s subsidiary MediPharm Labs Inc. is to provide filling of concentrate; labeling; and packaging services for Cronos Group. The agreement’s term is two years, but it carries an option for renewal.
“On the eve of legalization of concentrates products in Canada, we are delighted to add Cronos Group, to our expanding turnkey white-label platform,” MediPharm CEO Pat McCutcheon said in a statement.
“By leveraging our specialized expertise, technology and industrial scale vape filling capabilities, we will assist Cronos Group in delivering high quality, purity assured and Health Canada approved derivative products further advancing their industry leading reputation and enhancing the supply chain in this important new category.”
Click here for more information about the upcoming Benzinga Cannabis Capital Conference Oct. 22-23 in Chicago.
This is not the first time the two companies collaborated, MediPharm said. Previously, the company signed a private label bulk resin supply agreement and a cannabis concentrate program agreement with Cronos Group in May.
“Working with MediPharm Labs gives us the quality and optionality that we are looking for as we introduce our proprietary vape pen formulations,” Cronos CEO Mike Gorenstein said in a statement.
“We are committed to continuing to the lead the industry responsibly as derivative products are introduced to the expanding Canadian marketplace.”
MediPharm shares were up 2.09% at the time of publication, while Cronos shares were down 2.28%.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.